Nurix Therapeutics (NRIX) announced the appointment of John Northcott as chief commercial officer. From 2022 through 2024, Mr. Northcott served as CCO of Arvinas (ARVN), where he built a commercial infrastructure in support of the potential launch of a novel estrogen receptor degrader for the treatment of breast cancer.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NRIX:
- Nurix Therapeutics Unveils 2025 Objectives and Achievements
- Nurix Therapeutics outlines 2025 goals, objective
- Nurix Therapeutics sees cash runway into 1H27
- Nurix Therapeutics receives U.S. FDA Fast Track designation for NX-5948
- Nurix Therapeutics price target raised to $35 from $30 at H.C. Wainwright